|
| Treatment With Requip |
Restless Legs Syndrome (RLS) is a neurologic movement disorder characterized by an irresistible urge to move the legs, especially when at rest. [1] Requip is indicated for the treatment of moderate-to-severe primary RLS.
Requip targets a proposed underlying cause of RLS [15] and provides significant symptom improvement. [6-8,16]
Click on the links below for more information about treating RLS with Requip. |
|
|
Requip is indicated for patients with moderate-to-severe primary RLS.
Requip has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur, particularly during initial treatment or dose titration. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole.
For More Safety Information about Requip, click here.
Complete Prescribing Information for Requip® (ropinirole HCl) Tablets
|
This site is intended for US healthcare professionals only.
© 1997-2008 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us
|
|
|
